Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Motegrity
Generic Name
Prucalopride
Active Ingredient
PrucaloprideCategory
Serotonin-4 Receptor Agonist [EPC]
Salt Form
Succinate
Variants
2
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Motegrity, you must consult a qualified healthcare professional.
Detailed information about Motegrity
Prucalopride is a selective serotonin-4 (5-HT4) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults. It works by enhancing colonic motility and stimulating high-amplitude propagating contractions.
For the treatment of Chronic Idiopathic Constipation (CIC) in adults, the standard recommended dose of Prucalopride is 2 mg taken orally once daily. Clinical studies have shown that doses higher than 2 mg do not provide additional efficacy and may increase the risk of side effects. Healthcare providers typically assess the effectiveness of the medication after 4 weeks of continuous use. If the patient has not experienced a significant improvement in bowel movement frequency by that time, the physician may re-evaluate the treatment plan.
As of 2026, the safety and effectiveness of Prucalopride in pediatric patients (children under the age of 18) have not been established. Clinical trials in children have been conducted, but the drug is not currently FDA-approved for this population. Parents should never give Prucalopride to a child unless specifically directed by a pediatric specialist in a clinical trial or highly specialized setting.
Because Prucalopride is primarily excreted by the kidneys, dosage adjustments are necessary for patients with decreased kidney function.
For patients aged 65 and older, the starting dose is often 1 mg once daily. If this dose is well-tolerated but does not produce the desired effect, the healthcare provider may increase the dose to 2 mg once daily. This cautious approach accounts for the potential for age-related declines in kidney function.
Prucalopride should be taken exactly as prescribed by your doctor.
If you miss a dose of Prucalopride, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not take two doses at once to make up for a missed one, as this increases the risk of side effects like severe headache or diarrhea.
In the event of an overdose, patients may experience an intensification of known side effects, particularly severe headache, nausea, and diarrhea. If you suspect an overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment for overdose is generally supportive, focusing on hydration and managing symptoms. Because Prucalopride is highly selective, cardiovascular toxicity is unlikely, but medical monitoring is still essential.
> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or stop taking Prucalopride without medical guidance, as your symptoms may return.
Side effects from Prucalopride are most common during the first few days of treatment and often subside as the body adjusts to the medication. The most frequently reported side effects include:
Prucalopride is a potent prokinetic agent and should only be used by individuals for whom it has been specifically prescribed. It is not a 'rescue' laxative for occasional constipation but a maintenance therapy for chronic conditions. Patients should be aware that while the drug is highly selective, it affects the entire gastrointestinal tract and can interact with various physiological systems.
No FDA black box warnings for Prucalopride. The medication has been determined to have a favorable safety profile when used according to the approved labeling. Unlike previous drugs in this class, Prucalopride does not carry a black box warning for cardiovascular events.
Patients with a known hypersensitivity to Prucalopride succinate or any of the inactive ingredients (such as lactose) should not take this medication. Signs of a serious reaction include skin rash, itching, and swelling of the extremities or face.
There are no medications that are strictly contraindicated (absolutely forbidden) for use with Prucalopride based on chemical incompatibility. However, Prucalopride should never be used in patients with intestinal perforation or severe inflammatory bowel diseases. Using Prucalopride in the presence of a mechanical bowel obstruction can lead to severe complications, including bowel rupture.
There are specific medical scenarios where Prucalopride must NEVER be used because the risks far outweigh any potential benefits.
As of 2026, Prucalopride is generally not recommended during pregnancy. It is classified by many regulatory bodies in a category suggesting that while animal studies may not show direct fetal harm, there is 'limited data' in human pregnancies.
Prucalopride is excreted in human breast milk. While the amount a nursing infant would ingest is relatively low, the long-term effects of exposure to a prokinetic agent on a developing infant's gastrointestinal and nervous systems are unknown.
Prucalopride is a selective, high-affinity 5-HT4 (serotonin-4) receptor agonist. Serotonin receptors are found throughout the body, but the 5-HT4 subtype is specifically involved in the regulation of gastrointestinal motility.
When Prucalopride binds to these receptors on the enteric neurons within the myenteric plexus (the 'brain of the gut'), it stimulates the release of excitatory neurotransmitters, primarily acetylcholine. This release triggers a coordinated contraction of the smooth muscle in the colon. Most importantly, Prucalopride induces High-Amplitude Propagating Contractions (HAPCs). These are the specific types of bowel movements that move large amounts of waste through the colon toward the rectum. Unlike osmotic laxatives that just pull water into the stool, Prucalopride restores the natural 'pumping' action of the bowel.
Common questions about Motegrity
Prucalopride is a prescription medication specifically FDA-approved for the treatment of Chronic Idiopathic Constipation (CIC) in adults. It is used when other treatments, such as lifestyle changes or over-the-counter laxatives, have not provided sufficient relief. Unlike standard laxatives, Prucalopride works by stimulating the natural movement of the muscles in your colon to help you have more regular bowel movements. It belongs to a class of drugs called 5-HT4 receptor agonists, which target the serotonin receptors in the gut. Your doctor may prescribe it to help increase the frequency and completeness of your bowel movements over the long term.
The most common side effects reported by patients taking Prucalopride include headache, nausea, abdominal pain, and diarrhea. In clinical trials, these symptoms were most prevalent during the first few days of treatment and often resolved as the body adjusted to the medication. Headaches, in particular, are very common on the first day but usually disappear within 48 hours. If these side effects are severe or do not go away after the first week, you should contact your healthcare provider. Diarrhea that leads to dehydration or severe cramping should be reported immediately to ensure your safety.
There is no known direct chemical interaction between alcohol and Prucalopride that would make the combination dangerous. However, alcohol is known to irritate the digestive tract and can cause symptoms like nausea, bloating, or diarrhea, which may overlap with or worsen the side effects of Prucalopride. Additionally, alcohol can contribute to dehydration, which is counterproductive when treating chronic constipation. For the best results and to minimize discomfort, it is generally recommended to limit or avoid alcohol while you are starting Prucalopride. Always discuss your alcohol consumption habits with your doctor when starting a new medication.
The safety of Prucalopride during pregnancy has not been fully established, and it is generally recommended to avoid its use unless the benefits clearly outweigh the potential risks. There is limited data on how the drug affects human fetal development, although animal studies have not shown direct harm. If you are pregnant or planning to become pregnant, you must discuss alternative constipation management strategies with your obstetrician or gastroenterologist. Many doctors prefer to use older, more established treatments with better-known safety profiles during pregnancy. If you accidentally take Prucalopride while pregnant, notify your doctor immediately to discuss potential monitoring or enrollment in a pregnancy registry.
While some patients may experience a bowel movement within a few hours of their first dose, it typically takes 2 to 3 days of consistent use to see a significant change in bowel habits. Prucalopride is designed as a daily maintenance medication rather than a one-time 'rescue' laxative. Doctors usually evaluate the full effectiveness of the drug after about 4 weeks of continuous treatment. If you have not seen a significant improvement in your symptoms after a month, your healthcare provider may decide to adjust your dose or try a different medication. Consistency is key, so try to take the medication at the same time every day.
Prucalopride is not known to cause physical dependence or a 'withdrawal syndrome' if you stop taking it suddenly. However, because it treats a chronic condition, your constipation symptoms will likely return once the medication is no longer in your system. It is always best to consult with your healthcare provider before stopping any long-term prescription medication. They may want to check if your condition has improved enough to manage it with diet and fiber alone. If you experience any unusual symptoms after stopping the drug, report them to your doctor right away.
If you miss a dose of Prucalopride, you should take it as soon as you remember on that same day. However, if it is already close to the time for your next scheduled dose, you should skip the missed dose and simply take the next one at your regular time. Never take two doses at once to make up for a missed one, as this significantly increases the risk of experiencing a severe headache or intense abdominal cramping. To help you remember your doses, try using a pill organizer or setting a daily alarm on your phone. Maintaining a steady level of the medication in your blood is important for its effectiveness.
Weight gain is not a commonly reported side effect of Prucalopride in clinical trials. In fact, by improving bowel motility and reducing the bloating associated with chronic constipation, some patients may actually feel 'lighter' or experience a slight reduction in abdominal girth. If you notice significant or rapid weight changes while taking this medication, it is likely due to other factors such as changes in diet, activity levels, or other underlying health conditions. Always discuss unexpected weight changes with your healthcare provider to determine the cause. Prucalopride does not affect metabolic rate or appetite in a way that typically leads to fat accumulation.
Prucalopride can be taken with many other medications, but some interactions do exist. For example, anticholinergic drugs (which slow down the gut) can interfere with Prucalopride’s ability to stimulate bowel movements. Conversely, taking it with other prokinetic drugs might cause excessive GI stimulation. Because Prucalopride is not heavily processed by the liver's CYP450 enzymes, it has fewer 'drug-drug' interactions than many other medications. However, you should always provide your doctor with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you are taking. This ensures that your entire medication regimen is safe and effective.
As of 2026, generic versions of Prucalopride may be available in some regions, but availability depends on the patent status in your specific country. In the United States, the brand name Motegrity held patent exclusivity for several years following its 2018 approval. Generic medications contain the same active ingredient and meet the same safety and efficacy standards as the brand-name version, often at a lower cost. You can check with your pharmacist or insurance provider to see if a generic version is covered under your plan. If a generic is not yet available, your doctor may be able to assist with patient access programs offered by the manufacturer.
Other drugs with the same active ingredient (Prucalopride)
While Prucalopride is generally well-tolerated, certain symptoms require immediate medical intervention.
> Warning: Stop taking Prucalopride and call your doctor immediately if you experience any of the following:
Data on the long-term use of Prucalopride (over 12-18 months) suggests that the drug maintains its efficacy and safety profile. There is no evidence that Prucalopride causes 'lazy bowel syndrome' or dependency in the way that some stimulant laxatives (like senna or bisacodyl) might. However, patients should be monitored periodically to ensure the drug is still necessary and effective for their condition.
As of 2026, there are no FDA black box warnings for Prucalopride. However, the FDA does require a specific warning in the 'Warnings and Precautions' section regarding suicidal ideation and behavior. This was added based on a small number of cases observed during clinical development, and patients are advised to monitor their mood closely.
Report any unusual symptoms or changes in your mental health to your healthcare provider immediately. It is helpful to keep a 'symptom diary' during the first two weeks of treatment to track how your body responds to the medication.
Prucalopride should not be used if there is a known or suspected mechanical obstruction of the bowel or if the patient has a condition that increases the risk of intestinal perforation (a hole in the wall of the gut). Conditions like Crohn's disease, ulcerative colitis, or toxic megacolon are high-risk factors.
Healthcare providers and patients should be alert to the emergence of suicidal thoughts and behaviors, new or worsening depression, or other unusual changes in mood or behavior. If these symptoms occur, the medication should be discontinued immediately, and the patient should seek psychiatric evaluation. This warning applies to patients with and without a history of psychiatric disorders.
While Prucalopride is highly selective for the 5-HT4 receptor and does not typically affect the QT interval (a measure of heart rhythm), patients with a history of severe arrhythmias or significant heart disease should still use the drug with caution and under close medical supervision.
Routine laboratory monitoring (such as frequent blood draws) is generally not required for healthy adults taking Prucalopride. However, specific populations may need:
Prucalopride has been associated with dizziness and fatigue in some patients, particularly during the first few days of treatment. Use caution when driving or operating heavy machinery until you know how the medication affects you.
There is no known direct chemical interaction between Prucalopride and alcohol. However, alcohol can irritate the gastrointestinal tract and may worsen side effects like dizziness or nausea. It is generally advisable to limit alcohol consumption while managing chronic constipation.
Prucalopride does not typically require a tapering schedule (gradually reducing the dose). It can usually be stopped abruptly without withdrawal symptoms. However, stopping the medication will likely result in the return of constipation symptoms. Always discuss your plan to stop the medication with your doctor first.
> Important: Discuss all your medical conditions, including any history of depression or kidney disease, with your healthcare provider before starting Prucalopride.
Prucalopride is not known to interfere with common laboratory tests, such as blood glucose, liver enzymes, or urine drug screens. However, always inform the laboratory staff and your doctor that you are taking this medication before any diagnostic testing.
For each major interaction, the mechanism is usually either pharmacodynamic (the drugs have opposing or additive effects on the body) or pharmacokinetic (one drug changes how the other is absorbed or excreted). The clinical consequence is typically either reduced effectiveness of the constipation treatment or an increase in GI-related side effects. The management strategy usually involves adjusting the timing of doses or choosing alternative medications for non-constipation issues.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter laxatives and vitamins.
These are conditions where the doctor must carefully weigh the risks and benefits before prescribing Prucalopride:
There is no known cross-sensitivity between Prucalopride and other classes of laxatives (like osmotic or stimulant laxatives). However, if a patient has had a severe reaction to other serotonin-related drugs (like 5-HT3 antagonists used for nausea, such as ondansetron), the physician may exercise additional caution, although the receptor targets are different.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of abdominal surgery or inflammatory conditions, before prescribing Prucalopride.
Prucalopride is not approved for use in children under the age of 18. Clinical trials have not sufficiently demonstrated that the drug is effective or safe for the developing gastrointestinal tracts of pediatric patients. Growth and developmental effects have not been long-term studied in this population.
In clinical trials, approximately 15% of participants were 65 years of age or older.
The kidneys are the primary route for Prucalopride elimination.
> Important: Special populations require individualized medical assessment and should never start Prucalopride without a detailed consultation with a specialist.
| Parameter | Value |
|---|---|
| Bioavailability | >90% |
| Protein Binding | ~30% (primarily to albumin) |
| Half-life | 24 - 30 hours |
| Tmax | 2 - 3 hours |
| Metabolism | Minimal (Minor CYP3A4 involvement) |
| Excretion | Renal (~60% unchanged), Fecal (~4%) |
Prucalopride is classified as a Gastrointestinal Prokinetic Agent and a Serotonin-4 Receptor Agonist. It is the first drug in this class to be approved for CIC in the United States that does not have the severe cardiovascular restrictions associated with its predecessors. It is often grouped with other motility agents like linaclotide or plecanatide, though those drugs work via different mechanisms (guanylate cyclase-C agonists).